Amy Wong - 23 Aug 2023 Form 4 Insider Report for Apexigen, Inc.

Footnote F1

The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.

Footnote F2

Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.

Footnote F3

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,852 shares of Pyxis common stock at an exercise price of $7.37 per share.

Footnote F4

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 1,502 shares of Pyxis common stock at an exercise price of $8.53 per share.

Footnote F5

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 39,761 shares of Pyxis common stock at an exercise price of $9.63 per share.

Footnote F6

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 2,650 shares of Pyxis common stock at an exercise price of $13.05 per share.

Footnote F7

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 2,385 shares of Pyxis common stock at an exercise price of $13.05 per share.

Footnote F8

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 12,274 shares of Pyxis common stock at an exercise price of $20.99 per share.

Footnote F9

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 4,947 shares of Pyxis common stock at an exercise price of $26.61 per share.

Footnote F10

The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 4,417 shares of Pyxis common stock at an exercise price of $26.61 per share.

Footnote F11

The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2021. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 2,649 shares of Pyxis common stock at an exercise price of $26.61 per share.

Footnote F12

The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2022. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 13,248 shares of Pyxis common stock at an exercise price of $14.27 per share.